Actively Recruiting
Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.
Led by Novartis Pharmaceuticals · Updated on 2026-04-15
3000
Participants Needed
1
Research Sites
232 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This non-interventional study (NIS) aims to evaluate effectiveness, persistence, treatment patterns, adverse events (AEs), and patient-reported experience (including adherence, treatment satisfaction, health-related quality of life \[HRQoL\], work productivity, and etc.), among HR+/HER2- stage II and III eBC patients treated with ribociclib + ET, and to evaluate AEs and patients-reported experience among HR+/HER2- stage II and III eBC patients treated with abemaciclib + ET, as per local label.
CONDITIONS
Official Title
Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female patients
- Diagnosed with breast cancer according to ICD-9-CM or ICD-10-CMC codes
- At least 18 years old (or local legal age of consent) at initial breast cancer diagnosis
- Anatomic stage II or III breast cancer based on AJCC criteria
- Started adjuvant therapy with ribociclib or abemaciclib plus endocrine therapy within 14 days prior to enrollment
- Hormone receptor-positive status (ER+, PR+, or both) confirmed by biomarker testing before therapy start
- HER2-negative status confirmed by biomarker testing before therapy start
You will not qualify if you...
- Breast cancer recurrence (local or distant) before starting ribociclib or abemaciclib
- Participation in clinical trials with study drugs within 12 months before enrollment
- Physically or mentally unable to understand study requirements or complete data collection, needing legal representative support
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Novartis Investigative Site
London, United Kingdom, SW3 6JJ
Actively Recruiting
Research Team
N
Novartis Pharmaceuticals
CONTACT
N
Novartis Pharmaceuticals
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here